The event will present a range of innovations and opportunities to advance dPCR applications, integration & implementation and liquid biopsies for early detection, diagnosis, and monitoring.
This Year's Event Includes...
Over 700 attendees across the NextGen Omics series, representing internationally renowned academic institutions, research institutes and hospitals as well as global pharmaceutical organisations and leading biotech companies
Over 15 case studies, presentations, and panel discussions focused on highlighting the key synergies between dPCR and NGS systems to increase workflow efficiency in clinical settings
Maximise your event experience with exclusive interactive programme features such as workshops, panel discussions and roundtables, tapping into the priorities & challenges of the wider dPCR and liquid biopsies market
Agenda at a Glance
Day One: Clinical Genomics Focused Sessions
- Advanced imaging techniques & approaches
- Innovative methods to detect biomarkers
- Case studies from:
- Cardiovascular
- Metabolic
- Neurological
- Respiratory
- Genetic & rare diseases
- CRISPR-based diagnostics approaches
- Vaccine development with omics approaches
- Using omics to characterise infectious agents
- Multi omics in viral studies in pathology of infectious diseases
- Viral surveillance
- Data driven & omics-based approaches for identifying novel clinical indications
- Tools for analysing high-throughput sequencing data
- Bioinformatics and computational analysis tools for NGS data
- Spatial / single cell bioinformatics approaches
Part 1: Cancer
- CAR-T cell treatments
- Characterising immune cell subsets
- Cancer immunotherapy
Part 2: Metabolic & Cardiovascular Diseases (Non-Infectious Diseases)
- Optimising therapeutic design of cell & gene therapies
- Applying single-cell multi-omics to advanced therapy development
- Understanding mechanisms of action & treatment optimisation
- Multi-omics integration in microbiome studies
- Host-microbiome interactions
- AI/ML and sequencies technologies, single cell analysis
- What is a healthy microbiome?
- What can we do to intervene to modify the microbiome? Changing the composition of microbiome
Day Two
Part 1: In Oncology
- Mutation analysis
- Understanding tumor heterogeneity with dPCR
- Drug efficacy monitoring
Part 2: In Microbiology
- Infectious disease detection
- Anti-microbial resistance
- Microbial quantification
- Viral load monitoring
Day Three
- Assessing potential in personalised medicine, targeted drug monitoring, and clinical trials
- Single-cell analysis in liquid biopsy
- Advances in analysing cell-free DNA, CTCs, cell-free RNA, micro-RNA, mtDNA and DNA methylation
- Choosing correct isolation and characterisation techniques
- Plasma analysis techniques
- Liquid biopsies as a cancer screening tool for patient selection
- Liquid biopsy workflows
- Integrating liquid biopsy into clinical development